BRPI0407424A - Inibidores do fator inibitório da migração de macrófagos e métodos para a sua identificação - Google Patents
Inibidores do fator inibitório da migração de macrófagos e métodos para a sua identificaçãoInfo
- Publication number
- BRPI0407424A BRPI0407424A BR0407424-6A BRPI0407424A BRPI0407424A BR PI0407424 A BRPI0407424 A BR PI0407424A BR PI0407424 A BRPI0407424 A BR PI0407424A BR PI0407424 A BRPI0407424 A BR PI0407424A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- identification
- inhibitory factor
- mif
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 title 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 title 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"INIBIDORES DO FATOR INIBITóRIO DA MIGRAçãO DE MACRóFAGOS E MéTODOS PARA A SUA IDENTIFICAçãO". São providos inibidores do MIF os quais têm utilidade no tratamento de uma variedade de distúrbios, incluindo o tratamento de condições patológicas associadas com a atividade do MIF. Os inibidores do MIF possuem as estruturas seguintes (Ia), (Ib) incluindo estereoisómeros, prodrogas e seus sais farmaceuticamente aceitáveis, onde n, R~ 1~, R~ 2~, R~ 3~, R~ 4~, X, e Z são como aqui definidos. São também providas composições contendo um inibidor do MIF em combinação com um veículo farmaceuticamente aceitável, bem como métodos para a sua utilização.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44842703P | 2003-02-14 | 2003-02-14 | |
PCT/US2004/004433 WO2004074218A2 (en) | 2003-02-14 | 2004-02-13 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0407424A true BRPI0407424A (pt) | 2006-01-24 |
Family
ID=32908587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0407424-6A BRPI0407424A (pt) | 2003-02-14 | 2004-02-13 | Inibidores do fator inibitório da migração de macrófagos e métodos para a sua identificação |
Country Status (23)
Country | Link |
---|---|
US (7) | US7173036B2 (pt) |
EP (1) | EP1594501A4 (pt) |
JP (1) | JP2006517977A (pt) |
KR (1) | KR20050106430A (pt) |
CN (1) | CN1750823A (pt) |
AR (1) | AR043190A1 (pt) |
AU (1) | AU2004213408A1 (pt) |
BR (1) | BRPI0407424A (pt) |
CA (1) | CA2514862A1 (pt) |
CL (1) | CL2008001813A1 (pt) |
CO (1) | CO5640090A2 (pt) |
EC (1) | ECSP056020A (pt) |
HR (1) | HRP20050733A2 (pt) |
MX (1) | MXJL05000031A (pt) |
MY (1) | MY142846A (pt) |
NO (1) | NO20054218L (pt) |
PE (1) | PE20050274A1 (pt) |
PL (1) | PL378113A1 (pt) |
RU (1) | RU2005128190A (pt) |
TW (1) | TW200418829A (pt) |
UY (1) | UY28187A1 (pt) |
WO (1) | WO2004074218A2 (pt) |
ZA (1) | ZA200507170B (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
WO2005021546A1 (en) * | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
DE102004029573A1 (de) * | 2004-06-18 | 2005-12-29 | Gambro Lundia Ab | MIF-Adsorbent |
DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
CA2600175A1 (en) * | 2005-03-24 | 2006-03-20 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
EP1963271B1 (en) * | 2005-12-05 | 2010-07-28 | Merck Sharp & Dohme Corp. | Quinolone m1 receptor positive allosteric modulators |
GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
CN101516853A (zh) * | 2006-09-29 | 2009-08-26 | 泰博特克药品有限公司 | 喹啉酮衍生物 |
DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
MX2010010198A (es) * | 2008-03-20 | 2010-12-21 | Carolus Therapeutics Inc | Metodos para tratamiento de inflamacion. |
CA2716628A1 (en) * | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
US8791146B2 (en) * | 2008-05-29 | 2014-07-29 | Bayer Intellectual Property Gmbh | 2-alkoxy-substituted dicyanopyridines and their use |
EP2679238A1 (en) * | 2008-10-02 | 2014-01-01 | Celtaxsys, INC. | Methods of modulating the negative chemotaxis of immune cells |
WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
US20110256130A1 (en) * | 2008-12-01 | 2011-10-20 | Joshua Robert Schultz | Methods of treating inflammatory disorders |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
US20100158829A1 (en) | 2008-12-24 | 2010-06-24 | Conopco, Inc., D/B/A Unilever | Method and Composition for Color Modulation |
DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
PT2592933T (pt) * | 2010-07-16 | 2017-05-23 | Gaweco Anderson | Inibidores de mif e suas utilizações |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
US9133164B2 (en) * | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
DE102011106984B3 (de) * | 2011-07-08 | 2012-10-11 | Sartorius Stedim Biotech Gmbh | Microarray-Vorrichtung für das Screenen oder Auffinden von HSP90 Inhibitoren und von Inhibitoren weiterer krankheitsrelevanter Zielstrukturen |
EP2863920B1 (en) | 2012-06-20 | 2023-03-22 | Eutropics Pharmaceuticals, Inc. | Quinoline derivatives for use in the tratment of breast cancer |
US20160038503A1 (en) | 2012-11-21 | 2016-02-11 | David Richard | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
CN103045608A (zh) * | 2012-12-17 | 2013-04-17 | 中国水产科学研究院东海水产研究所 | 一种拟穴青蟹巨噬细胞移动抑制因子基因mif及其用途 |
WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
JP6538044B2 (ja) | 2013-10-30 | 2019-07-03 | ユートロピクス ファーマシューティカルズ, インコーポレイテッド | 化学療法感受性および化学毒性を判定する方法 |
GB2524586A (en) | 2014-03-28 | 2015-09-30 | Univ Dublin | Macrophage migration inhibitory factor (MIF) inhibitors |
CN104447693B (zh) * | 2014-10-24 | 2016-08-24 | 苏州昊帆生物科技有限公司 | 喹啉酮衍生物及其制备方法和应用 |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
WO2018034917A1 (en) | 2016-08-15 | 2018-02-22 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
EP3496716B1 (en) | 2016-08-15 | 2021-11-03 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
WO2020143626A1 (zh) * | 2019-01-08 | 2020-07-16 | 南京药捷安康生物科技有限公司 | Pde9抑制剂及其用途 |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
CN115003665A (zh) * | 2019-11-28 | 2022-09-02 | 拜耳公司 | 作为免疫活化的DGKα抑制剂的取代的氨基喹诺酮 |
CN115210225A (zh) | 2019-11-28 | 2022-10-18 | 拜耳公司 | 取代的氨基喹诺酮类作为免疫激活的dgkalpha抑制剂 |
EP4065584A1 (en) | 2019-11-28 | 2022-10-05 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
IL294269A (en) * | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substitute quinolinyl piperazine compounds are useful as t-cell activators |
CN113233990B (zh) * | 2021-05-13 | 2022-09-23 | 江苏超跃化学有限公司 | 一种5-氯-2-氨基苯甲酸中间体的制备方法 |
WO2023165504A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54165896U (pt) * | 1978-05-15 | 1979-11-21 | ||
US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
US4299814A (en) * | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
HU200794B (en) * | 1984-02-22 | 1990-08-28 | Wellcome Found | Process for expressing malaria antigenes |
US5700447A (en) * | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5733524A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5733933A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5801200A (en) * | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
AU592753B2 (en) | 1984-05-24 | 1990-01-25 | Ciba-Geigy Ag | Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications |
JPH0672158B2 (ja) | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
US4708937A (en) * | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8602626D0 (en) * | 1986-02-04 | 1986-03-12 | Ciba Geigy Ag | Neurite-promoting factor |
EP0263072B1 (en) | 1986-10-03 | 1994-03-23 | Ciba-Geigy Ag | Novel lymphokine related peptides |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990011301A1 (en) | 1989-03-17 | 1990-10-04 | Genetics Institute, Inc. | Human macrophage migration inhibitory factor |
FI82144C (fi) * | 1989-03-22 | 1991-01-10 | Wallac Oy | Foerfarande foer samtidig bestaemning av flera ligander. |
GB8915414D0 (en) * | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
US5328990A (en) * | 1991-04-26 | 1994-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of macrophage migration inhibition factor from ocular lens |
CA2054602C (en) * | 1991-10-31 | 2003-04-22 | Anthony Pawson | Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
US6030615A (en) * | 1993-05-17 | 2000-02-29 | The Picower Institute For Medical Research | Combination method for treating diseases caused by cytokine-mediated toxicity |
EP1741779A3 (en) | 1993-05-17 | 2010-03-24 | The Picower Institute For Medical Research | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity |
US5650295A (en) * | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
SI9400363A (en) | 1994-09-19 | 1996-08-31 | Mozetic Francky Bojana | Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein |
WO1996015242A2 (en) | 1994-11-16 | 1996-05-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor |
US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
US6420188B1 (en) * | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
JP2000512737A (ja) | 1996-04-18 | 2000-09-26 | アリアッド ファーマスーティカルズ,インク. | 試験管内蛍光偏光検定法 |
US5883224A (en) * | 1996-04-19 | 1999-03-16 | Cytokine Sciences, Inc. | Characterization of transfer factors and methods of use |
US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
US6413939B1 (en) * | 1997-10-31 | 2002-07-02 | The Picower Institute For Medical Research | Inducible phosphofructokinase and the Warburg effect |
DK1036192T3 (da) | 1997-12-05 | 2003-06-10 | Upjohn Co | Fluorescensbaserede screeningsanalyser med høj hastighedforproteinkinaser og phosphataser |
JP2002521690A (ja) * | 1998-07-28 | 2002-07-16 | バイオメトリック イメージング インコーポレイテッド | 細胞運動性アッセイのための装置および方法 |
US6214343B1 (en) * | 1999-05-24 | 2001-04-10 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of necrotizing enterocolitis |
CA2389229A1 (en) | 1999-10-29 | 2001-05-10 | The Picower Institute For Medical Research | Compounds having mif antagonist activity |
EP1465660A4 (en) | 2001-01-12 | 2005-09-21 | Cytokine Pharmasciences Inc | METHOD AND COMPOSITIONS FOR MODULATING THE REGULATION OF THE CYTOTOXIC LYMPHOCYTE RESPONSE BY MACROPHAGE MIGRATION HEMM FACTOR |
AU2002255961B2 (en) | 2001-03-29 | 2007-08-23 | Baxalta GmbH | Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
MY140679A (en) * | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
CA2459224C (en) | 2001-09-03 | 2012-05-08 | Takeda Chemical Industries, Ltd. | 1,3-benzothiazinone derivatives and the use thereof |
AU2002365941A1 (en) | 2001-12-05 | 2003-09-02 | North Shore-Long Island Jewish Research Institute | Methods of diagnosis, monitoring and treatment of fertility |
US20040019921A1 (en) * | 2001-12-19 | 2004-01-29 | Fingerle-Rowson Gunter R. | Non-human mammal with disrupted or modified MIF gene, and uses thereof |
US20060034832A1 (en) | 2002-04-26 | 2006-02-16 | Haruhide Kimura | Cell death inhibitor |
CA2487838A1 (en) | 2002-06-07 | 2003-12-18 | Cortical Pty Ltd | Methods and compounds for inhibiting the cytokine or biological activity of mif |
CN1675154A (zh) | 2002-06-07 | 2005-09-28 | 科蒂科股份有限公司 | 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物 |
EP1568697A4 (en) | 2002-12-05 | 2006-03-08 | Takeda Pharmaceutical | 1,3-BENZOTHIAZINONE DERIVATIVES, THEIR MANUFACTURING METHOD AND USE |
TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
US7361474B2 (en) | 2003-02-24 | 2008-04-22 | United States Of America As Represented By The Department Of Veterans Affairs | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer |
WO2005021546A1 (en) * | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
-
2004
- 2004-02-06 TW TW093102732A patent/TW200418829A/zh unknown
- 2004-02-12 MY MYPI20040451A patent/MY142846A/en unknown
- 2004-02-13 MX MXJL05000031A patent/MXJL05000031A/es not_active Application Discontinuation
- 2004-02-13 CA CA002514862A patent/CA2514862A1/en not_active Abandoned
- 2004-02-13 US US10/778,884 patent/US7173036B2/en not_active Expired - Fee Related
- 2004-02-13 AU AU2004213408A patent/AU2004213408A1/en not_active Abandoned
- 2004-02-13 PL PL378113A patent/PL378113A1/pl unknown
- 2004-02-13 WO PCT/US2004/004433 patent/WO2004074218A2/en active Application Filing
- 2004-02-13 BR BR0407424-6A patent/BRPI0407424A/pt not_active IP Right Cessation
- 2004-02-13 CN CNA2004800043054A patent/CN1750823A/zh active Pending
- 2004-02-13 JP JP2006503598A patent/JP2006517977A/ja active Pending
- 2004-02-13 KR KR1020057014944A patent/KR20050106430A/ko not_active Application Discontinuation
- 2004-02-13 RU RU2005128190/04A patent/RU2005128190A/ru not_active Application Discontinuation
- 2004-02-13 EP EP04711246A patent/EP1594501A4/en not_active Withdrawn
- 2004-02-16 UY UY28187A patent/UY28187A1/es not_active Application Discontinuation
- 2004-02-16 AR ARP040100472A patent/AR043190A1/es not_active Application Discontinuation
- 2004-02-16 PE PE2004000161A patent/PE20050274A1/es not_active Application Discontinuation
-
2005
- 2005-08-18 CO CO05082095A patent/CO5640090A2/es not_active Application Discontinuation
- 2005-08-24 HR HR20050733A patent/HRP20050733A2/hr not_active Application Discontinuation
- 2005-09-07 ZA ZA200507170A patent/ZA200507170B/xx unknown
- 2005-09-12 NO NO20054218A patent/NO20054218L/no not_active Application Discontinuation
- 2005-09-14 EC EC2005006020A patent/ECSP056020A/es unknown
-
2006
- 2006-11-02 US US11/592,364 patent/US7312220B2/en not_active Expired - Fee Related
- 2006-11-03 US US11/593,190 patent/US7312221B2/en not_active Expired - Fee Related
- 2006-11-03 US US11/592,921 patent/US20070054923A1/en not_active Abandoned
- 2006-11-03 US US11/592,542 patent/US7235546B2/en not_active Expired - Fee Related
-
2007
- 2007-03-16 US US11/687,541 patent/US20070179132A1/en not_active Abandoned
- 2007-07-11 US US11/776,472 patent/US20070270395A1/en not_active Abandoned
-
2008
- 2008-06-18 CL CL200801813A patent/CL2008001813A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0407424A (pt) | Inibidores do fator inibitório da migração de macrófagos e métodos para a sua identificação | |
BR0209948A (pt) | Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos | |
BRPI0413695A (pt) | derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas | |
BR0008958A (pt) | Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc | |
EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
EA200501009A1 (ru) | Замещённые пирролопиразольные производные в качестве ингибиторов киназы | |
BR0311628A (pt) | Composto, processo para preparar e uso do mesmo, método para produzir um efeito inibitório do ibat em um animal de sangue quente, e, composição farmacêutica | |
BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
BRPI0414111A (pt) | inibidores heterocìclicos de mek e métodos de uso dos mesmos | |
GEP20053659B (en) | Aryl And Heteroaryl Urea CHK1 Inhibitors for Use as Radiosensitizers and Chamosensitizers | |
BRPI0414548A8 (pt) | derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso | |
SE0202463D0 (sv) | Novel compounds | |
BR0010080A (pt) | Inibidores de renina | |
BR0208373A (pt) | Inibidores da tirosina cinase | |
NZ593295A (en) | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor | |
ATE409486T1 (de) | Behandlung hyperproliferativer erkrankungen | |
GEP20053631B (en) | ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | |
WO2007109251A3 (en) | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | |
NO20062453L (no) | Tiozolidinoner, fremstilling og anvendelse derav som legemidler | |
BR0111383A (pt) | Benezenos 1,2,4-tri-substituìdos como inibidores de 15-lipoxigenase | |
NO20081804L (no) | Pyrazolforbindelser egnet til behandling av inflammasjon | |
NO20033665L (no) | Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer | |
BRPI0417943A (pt) | antagonistas de receptor de crf e métodos relacionados para essa finalidade | |
BRPI0511323A (pt) | tetraidroisoquinolinas substituìdas usadas na forma de inibidores de mmp, método para a produção e uso das mesmas na forma de drágeas | |
SE0202461D0 (sv) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |